https://www.selleckchem.com/products/gc7-sulfate.html Comparing the Lactobacillus and control groups, a significant reduction was found in the incidence of NEC (RR 0.34, 95% CI 0.25-0.46; P less then 0.00001) and death (RR 0.48, 95% CI 0.36-0.64; P less then 0.00001). No significant difference in the incidence of sepsis was found between the Lactobacillus and placebo groups (RR 0.90, 95% CI 0.72-1.12; P = 0.34). CONCLUSIONS Lactobacillus is safe and can prevent necrotizing enterocolitis in preterm infants. OBJECTIVE The aim of this study was to evaluate the survival outcomes of different prostate-specific antigens (PSA) levels in men with high-grade prostate cancer. MATERIALS AND METHODS From 2004 to 2015 in the Surveillance, Epidemiology, and End Results database, men diagnosed with clinically localized prostate cancer and a Gleason score (GS) 8-10 were identified. Patients were divided into the PSA levels 20.0 ng/ml groups. Multivariable Cox regressions and Kaplan-Meier analysis were adopted to analyze the prostate cancer-specific survival (PCSS). RESULTS 59,336 men with a median age of 70 (63-76) years with a GS 8-10 were included. The PCSS of patients with a PSA less then 4.0 ng/ml was significantly worse than that of patients with a PSA 4.0-10.0 ng/ml [hazard ratio (HR) 1.43 (1.28-1.58)], but was better than that of patients with a PSA 10.1-20.0 ng/ml [HR 1.18 (1.06-1.31)]. After stratifying patients by GS, the differences between patients with a PSA less then 4.0 ng/ml and a PSA 4.0-10.0 ng/ml were only significant in those with a GS 9 and 10 [GS 9 HR 1.49 (1.28-1.72); GS 10 HR 1.42 (1.12-1.8)], but not in those with a GS 8 [HR 1.04 (0.95-1.14)]. Moreover, the PCSS of patients with a PSA less then 4.0 ng/ml and a PSA 10.0-20.0 ng/ml were similar in patients with GS 9 and 10 diseases [GS 9 HR 1.06 (0.91-1.23); GS 10 HR 1.13 (0.89-1.44)]. CONCLUSIONS Patients with a PSA less then 4.0 ng/ml had poorer PCSS than patients with a PSA 4.0-10.0 ng/ml. Similar PCSS was